Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

AI-Driven Prediction of Dialysis Outcome With EHR

NCT06791447 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2023-01-01
Last updated
2025-04-17

Condition(s) studied

Dialysis Patients

Investigational drug(s) / intervention(s)

AI-assisted Predictive Model for Dialysis Outcomes

AI-assisted Predictive Model for Dialysis Outcomes: This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, dialysis treatment details, and clinical observations, to predict outcomes for dialysis patients. The model employs deep learning algorithms to predict mortality risk, intermediate outcomes such as anemia, blood pressure control, nutrition, and calcium-phosphate metabolism, and helps identify early signs of deterioration. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting patient outcomes and optimizing treatment strategies to improve overall health and survival rates for dialysis patients.

Study summary

This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for outcome of dialysis patients, leveraging multimodal health data.

Eligibility

Sex
ALL
Min age
20 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients who have been undergoing dialysis (either hemodialysis or peritoneal dialysis) for at least 3 months. 2. Complete and accessible EHR data, including medical history, laboratory test results, dialysis treatment details, and clinical observations. 3. Participants must provide informed consent for the use of their health data for research purposes. Exclusion Criteria: 1. Patients with incomplete or missing critical EHR data, including medical history, laboratory results, dialysis data, or treatment details necessary for the study. 2. Patients who have been on dialysis for less than 3 months, to ensure stable data for outcome prediction.

Primary outcome measure(s)

  • Mortality Prediction Accuracy — 1 year
    The ability of the AI-assisted predictive model to accurately predict the risk of mortality in dialysis patients. Prediction accuracy will be assessed using the Area Under the Curve (AUC), F1 score, and sensitivity/specificity. The model will be evaluated by comparing the predicted mortality risk with actual outcomes (i.e., whether patients survived or passed away during the study period).

Trial sites (1)

FacilityCityRegionStatus
General Hospital of PLA Beijing Beijing Municipality Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06791447 on ClinicalTrials.gov ↗ ← All trials in China